Unilever says GSK consumer arm 'strategic fit', flags restructure
17th Jan 2022 07:22
(Sharecast News) - Unilever on Monday maintained it was still keen to buy GSK's consumer healthcare arm, calling it a "strong strategic fit", despite having its latest £50bn offer rejected as it also flagged a restructure of the group later this month.
Read moreGlaxoSmithKline's ViiV Healthcare receives FDA approval for Apretude
21st Dec 2021 07:28
(Sharecast News) - Pharmaceutical giant GlaxoSmithKline said on Tuesday that ViiV Healthcare, its majority-owned subsidiary, had received approval from the Food and Drug Administration for Apretude, a long-acting injectable pre-exposure prophylaxis option that reduces the risk of sexually acquired HIV-1.
Read moreGlaxo appoints ex-Tesco boss as chair of new consumer healthcare business
20th Dec 2021 07:40
(Sharecast News) - GlaxoSmithKline has appointed former Tesco boss Sir Dave Lewis as chairman of its new consumer healthcare business with effect from 1 January 2022.
Read moreGlaxoSmithKline Covid treatment approved for use in EU
17th Dec 2021 14:02
(Sharecast News) - GlaxoSmithKline and Vir Biotechnology said on Friday that the European Commission has given marketing authorisation to Xevudy - sotrovimab - for the early treatment of Covid-19.
Read moreGSK-Sanofi Covid jab shows 'strong' immune response
15th Dec 2021 07:05
(Sharecast News) - A Covid-19 vaccine booster being developed by GlaxoSmithKline and Sanofi has been shown to be effective across all age groups tested, according to data released by the UK drugs firm on Wednesday.
Read moreMedicago and GSK's Covid-19 vaccine shows 75.3% efficacy against Delta strain
7th Dec 2021 12:56
(Sharecast News) - Medicago and GSK's Covid-19 vaccine showed a high degree of efficacy in blocking symptomatic disease in those infected with the Delta strain of SARS-CoV-2.
Read moreGSK-Vir drug works against all Omicron variants - study
7th Dec 2021 07:46
(Sharecast News) - GlaxoSmithKline and Vir Biotechnology on Tuesday said their antibody Covid-19 treatment was effective against all mutations of the Omicron variant, according to early-stage studies.
Read moreGSK says its Covid-19 treatment works on Omicron
2nd Dec 2021 07:26
(Sharecast News) - GlaxoSmithKline said its treatment for Covid-19 was effective in treating all tested variants of the virus including key mutations of the Omicron strain.
Read moreGlaxo poaches new head of vaccines Phil Dormitzer from Pfizer
30th Nov 2021 13:26
(Sharecast News) - GlaxoSmithKline said on Tuesday that it has appointed Phil Dormitzer as global head of vaccines R&D.
Read moreUS secures $1bn of GSK-Vir Covid-19 treatment - report
17th Nov 2021 09:42
(Sharecast News) - The United States has signed about $1bn of contracts to buy the antibody-based Covid-19 treatment developed by GlaxoSmithKline and Vir Technology of the US, according to a report.
Read moreEU approves Glaxo's Nucala treatment
17th Nov 2021 07:50
(Sharecast News) - GlaxoSmithKline said the European Commission has approved its Nucala treatment for asthma and other nasal conditions.
Read moreGlaxoSmithKline denies interest in Aurinia
1st Nov 2021 10:35
(Sharecast News) - British drugs group GlaxoSmithKline has denied speculation it is interested in acquiring Canada's Aurinia Pharmaceuticals.
Read moreSunday newspaper round-up: Heathrow, GSK, Roll-Royce
31st Oct 2021 15:25
(Sharecast News) - Plans for a third runway at Heathrow may have been dealt a fatal blow after Ferrovial balked at further investment. The Spanish infrastructure investor, Heathrow's top shareholder, signalled the move in protest over the Civial Aviation Authorities's decision to block a 90% rise in landing charges from 2022, which the company said meant shateholders would have to make do with lower returns. - Sunday Telegraph
Read moreGlaxo upgrades FY EPS guidance after strong Q3
27th Oct 2021 12:05
(Sharecast News) - GlaxoSmithKline upgraded its full-year earnings per share guidance on Wednesday as it posted a jump in third-quarter sales.
Read moreWednesday preview: Autumn Budget, GSK in focus
26th Oct 2021 15:15
(Sharecast News) - All eyes on Wednesday will be on the Chancellor´s budget statement, although according to Barclays Research, Rishi Sunak is unlikely "to alter the contours of the already restrictive policy mix meaningfully".
Read more